RecruitingNot ApplicableNCT06602843
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Sponsor
Anhui Provincial Hospital
Enrollment
70 participants
Start Date
Jan 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Ages 18-75;
- Radical operation for esophageal cancer;
- Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation were performed, and the stage was pIIB-IVA (AJCC eighth edition staging criteria: T≥3 or N+).
- More than or equal to 12 lymph nodes were surgically removed;
- Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy;
- Informed consent signed by patient or family member.
Exclusion Criteria6
- Less than 18 years old, more than 75 years old;
- did not receive radical resection of esophageal cancer, including palliative resection;
- Postoperative pathology showed non-esophageal squamous cell carcinoma;
- After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB (AJCC eighth edition staging standard); e. Less than 12 lymph nodes were surgically removed;
- Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy;
- The patient or family member did not sign the informed consent.
Interventions
PROCEDURENeoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06602843
Related Trials
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
NCT074031361 location
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632154 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT072171718 locations
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT0678011141 locations
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT0674758538 locations